Technology Innovation Institute and AI71 Collaborate with Amazon Web Services to Scale AI Innovations in the UAE and Beyond
21.5.2025 15:31:00 CEST | Business Wire | Press Release
Abu Dhabi’s Technology Innovation Institute (TII), the creator of the globally ranked Falcon series of AI models and security and privacy solutions, as well as AI71, a leading Abu Dhabi AI company delivering tailored enterprise products, are collaborating with Amazon Web Services (AWS) to expand access to made-in-the UAE AI models and solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521645833/en/
Technology Innovation Institute and AI71 Collaborate with Amazon Web Services to Scale AI Innovations in the UAE and Beyond (photo: AETOSWire)
By combining TII’s technical expertise in large language models (LLMs), AI71’s expertise in building advanced AI agents, and world-leading cloud-based AI and machine learning services from AWS, professionals worldwide will gain streamlined access to Falcon and customized AI solutions that transform how people live and work.
TII already offers multiple Falcon LLMs through Amazon SageMaker, and the latest models will also become available via the Amazon Bedrock Marketplace. The Falcon series features a wide range of models that have consistently ranked among the top performers globally, providing scalable solutions for diverse AI needs. Enterprises and developers will be able to integrate Falcon into their applications through pay-as-you-go APIs, reducing the need for large amounts of compute power.
AI71’s products, designed to empower professionals across sectors through selective automation and agentic workflows, are already available in the AWS Marketplace, providing access for millions of customers globally. AI71 will also work with AWS to accelerate development and enhancement of key products through rapid prototyping and early access.
Beyond increasing adoption of AI models and products, TII and AI71 aim to advance innovation together in several key areas using AWS technology and solutions:
- Increasing access to privacy and cybersecurity tools: TII’s PetalGuard, a privacy preserving solution designed to enhance data privacy and protection, will also be available in AWS Marketplace, making it easier for organizations worldwide to adopt advanced privacy-first technologies.
- Increasing AI privacy: TII and AWS will work together on cryptographic research, including fully homomorphic encryption and multi-party computation, to advance secure, privacy-preserving AI machine learning technologies.
- Product innovation and global expansion: AI71 and AWS will work together to rapidly prototype and launch new agentic AI solutions tailored to the needs of enterprises and governments.
- AI talent development: AWS will also help strengthen AI71’s training programs, using AWS-backed executive certifications to create industry-recognized AI credentials.
Together, the three organizations aim to become the go-to partner for governments, institutions, and nations seeking turnkey, world-class AI solutions at scale.
“At TII, we’re committed to pushing the boundaries of applied research to deliver real-world impact. By bringing Falcon and other AI products to AWS, we are bridging the gap between cutting-edge innovation and real-world application. A key part of this mission is our advancement of privacy-preserving machine learning, with novel frameworks that protect data throughout the AI lifecycle. We’re also making cutting-edge, research-driven AI more accessible and putting UAE technology on the map in a market dominated by a few legacy players,” said Dr. Najwa Aaraj, TII’s CEO.
“At AI71, we’re building the next generation of powerful AI companions designed to redefine how industries operate. Partnering with AWS enables us to scale faster, expand our offerings, and develop in international markets with greater speed and impact. It serves as a catalyst to test, refine, and strengthen our products beyond regional boundaries—accelerating innovation, unlocking new business models, and forging trusted partnerships with companies, governments, and institutions to drive enterprise AI adoption.” said Chiara Marcati, AI71’s Chief AI Advisory and Business officer.
“AWS is proud to advance our collaboration with TII and AI71, bringing the power of Falcon models to a wider audience,” said Tanuja Randery, Vice President, Europe, Middle East, and Africa, AWS. “Together, we’re empowering customers to build innovative AI-powered applications across diverse industries, from financial services to healthcare, all while maintaining control over their data.
“By offering Falcon through Amazon Bedrock, we’re giving customers the choice and flexibility to leverage these cutting-edge models within a secure and high-performing environment. Trained on AWS infrastructure, the Falcon models continue to impress technologists across the globe, centering the UAE at the forefront of the great global AI innovation race that is transforming government, business, culture, and society.”
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250521645833/en/
Contacts
Victoria Meven
Victoria.meven@edelman.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom